Middleton (10-1) flashed the form that earned him the moniker of Mississippi’s best collegiate baseball this spring, checking ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...

ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...